

The following is a summary of the principal features of the Units (the "Units") of the Healthcare Leaders Income ETF (the "Fund"). You can find more detailed information about the Fund in the prospectus. The prospectus is available on Harvest's website at [www.harvestportfolios.com](http://www.harvestportfolios.com), or by contacting Harvest at [info@harvestportfolios.com](mailto:info@harvestportfolios.com), or by calling toll-free 1.866.998.8298.

FUND DETAILS			
<b>Inception Date:</b>	November 19, 2014*	<b>RSP Eligibility:</b>	RRSPs, RRIFs, RESPs, DPSPs and TFSA's
<b>Ticker Symbol:</b>	HHL	<b>DRIP:</b>	Not Offered
<b>CUSIP:</b>	42227H101	<b>Portfolio Manager:</b>	Harvest Portfolios Group Inc.
<b>Currency</b>	CAD	<b>Management Expense Ratio (MER):</b>	1.38% <sup>1,2</sup>
<b>Distributions:</b>	Monthly, \$0.0583 per unit	<b>Exchange:</b>	TSX

\*The Fund was formerly known as "Healthcare Leaders Income Fund" and was originally established as a closed-end investment trust under the laws of Ontario on November 19, 2014 and was listed on the TSX on December 18, 2014. Healthcare Leaders Income Fund will convert from a closed-end fund into an exchange-traded fund on or about October 24, 2016 in accordance with amendments to its Declaration of Trust, as approved by Unitholders at a special meeting held on September 19, 2016 (the "Conversion").

## INVESTMENT OBJECTIVE

The Fund's investment objective is to provide Unitholders with: (i) the opportunity for capital appreciation; (ii) monthly cash distributions; and (iii) lower overall volatility of Portfolio returns than would otherwise be experienced by owning Equity Securities of the Healthcare Leaders directly. To achieve lower overall volatility of portfolio returns, the Fund will generally write covered call options on up to 33% of the portfolio securities. The level of covered call option writing may vary based on market volatility and other factors.

## INVESTMENTS OF THE FUND

The charts below are intended to give you a snapshot of the Fund's investments on September 30, 2016, prior to the Conversion. The Fund's investments will change.

Top 10 Positions	% of NAV	Investment Mix	
		Industry	% of NAV
Merck & Co., Inc.	5.6	Pharmaceutical Issuers	49.9
Zoetis Inc. Class A	5.5	Healthcare Equipment Issuers	15.7
Becton, Dickenson and Company	5.4	Biotechnology Issuers	15.5
Quest Diagnostics Inc.	5.4	Healthcare Services Issuers	5.4
Agilent Technologies, Inc.	5.2	Life Sciences Tools & Services Issuers	5.2
UnitedHealth Group Inc.	5.2	Managed Healthcare Issuers	5.2
Amgen Inc.	5.2	Healthcare Distributor Issuers	4.6
Gilead Sciences, Inc.	5.2	Cash and other assets and liabilities	0.5
Boston Scientific Corp.	5.1	Options	(0.3)
Medtronic PLC	5.1	Foreign Currency Forward Contracts	(1.7)
<b>Total % of Top 10 Investments</b>	<b>52.9</b>	<b>Total</b>	<b>100.0</b>

## RISK

All investments involve risk. When you invest in the Fund the value of your investment can go down as well as up. For a description of the specific risks of the Fund, see the Fund's prospectus.

## FUND EXPENSES

You don't pay these expenses directly. They affect you because they reduce the Fund's returns.

<b>Management Expense Ratio (MER)</b>	<b>Annual Rate (as a % of the Fund's value)</b>
<i>This is the total of the Fund's management fee and operating expenses.</i>	1.38% <sup>1,2</sup>
<b>Trading Expense Ratio (TER)</b>	
<i>These are the Fund's trading costs.</i>	0.10% <sup>2</sup>
<b>Fund Expenses</b>	1.48% <sup>1,2</sup>

The amount of fund expenses is the total amount arrived at by adding the MER and the TER, and is not a separate expense charged to the Fund.

<sup>1</sup> MER excluding offering expenses was 1.38% as at June 30, 2016, prior to the Conversion.

<sup>2</sup> As at June 30, 2016, prior to the Conversion.

## TRAILING COMMISSIONS

There are no trailing commissions paid on Units of the Fund.

## OTHER FEES

You may pay brokerage fees to your dealer when you purchase and sell Units of the Fund.

## STATEMENT OF RIGHTS

Under securities law in some provinces and territories, you have: (a) the right to cancel your purchase within 48 hours after you receive confirmation of the purchase, or (b) other rights and remedies if this document or the Fund's prospectus contains a misrepresentation. You must act within the time limit set by the securities law in your province or territory. For more information, see the securities law of your province or territory or ask a lawyer.